264 related articles for article (PubMed ID: 23442261)
1. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.
Chu HY; Jain R; Xie H; Pottinger P; Fredricks DN
BMC Infect Dis; 2013 Feb; 13():105. PubMed ID: 23442261
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
4. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
6. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
7. Management of voriconazole hepatotoxicity in a lung transplant patient.
Belaiche S; Roustit M; Bedouch P; Quetant S; Saint-Raymond C; Pison C
Transpl Infect Dis; 2011 Jun; 13(3):309-11. PubMed ID: 21176020
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
9. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.
Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M;
Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia.
Okamoto T; Koh K; Takita J; Furuya A; Kato M; Ida K
Pediatr Int; 2010 Feb; 52(1):137-41. PubMed ID: 20158658
[No Abstract] [Full Text] [Related]
12. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
14. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole.
Jacobs F; Selleslag D; Aoun M; Sonet A; Gadisseur A
Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):1173-9. PubMed ID: 21971820
[TBL] [Abstract][Full Text] [Related]
15. Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies.
Lee YJ; Lee SO; Choi SH; Kim YS; Woo JH; Chun S; Kim DY; Lee JH; Lee JH; Lee KH; Kim SH
Med Mycol; 2013 Apr; 51(3):324-30. PubMed ID: 22712456
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
Cordonnier C; Rovira M; Maertens J; Olavarria E; Faucher C; Bilger K; Pigneux A; Cornely OA; Ullmann AJ; Bofarull RM; de la Cámara R; Weisser M; Liakopoulou E; Abecasis M; Heussel CP; Pineau M; Ljungman P; Einsele H; ;
Haematologica; 2010 Oct; 95(10):1762-8. PubMed ID: 20634495
[TBL] [Abstract][Full Text] [Related]
17. [Voriconazole at Saint Louis Hospital (Paris): Analysis of two-years of compassionate use].
Papy E; Carde A; Ribaud P; Faure P; Touratier S
Presse Med; 2006 Feb; 35(2 Pt 1):251-2. PubMed ID: 16493359
[No Abstract] [Full Text] [Related]
18. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.
Spriet I; Grootaert V; Meyfroidt G; Debaveye Y; Willems L
Eur J Clin Pharmacol; 2013 Mar; 69(3):737-8. PubMed ID: 22878691
[No Abstract] [Full Text] [Related]
19. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.
Cadranel J; Philippe B; Hennequin C; Bergeron A; Bergot E; Bourdin A; Cottin V; Jeanfaivre T; Godet C; Pineau M; Germaud P
Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):3231-9. PubMed ID: 22782438
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
